Eribulin (HALAVEN®) Use for the Treatment of Advanced Breast Cancer

• Research type

  Research Study

• Full title

  Eribulin (HALAVEN®) Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry

• IRAS ID

  121653

• Contact name

  Hartmut Kristelait

• Contact email

  Hartmut.Kristeleit@gstt.nhs.uk

• Sponsor organisation

  Eisai Ltd.

• REC name

  South Central - Berkshire B Research Ethics Committee

• REC reference

  13/SC/0044

• Date of REC Opinion

  21 Jan 2013

• REC opinion

  Favourable Opinion